Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Michael Rothe

Has grant

Biologe

Hannover Medical School

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Recent Grants

Grant: Close

Untersuchungen zur klonalen Dynamik von Mesenchymalen Stammzellpopulationen

Open Date: 2016-01-01

Close Date: 2024-01-01

Articles (13)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (11)

Jordi Barquinero

Senior researcher, Group leader

Vall d'Hebron Institut de Recerca

SPAIN

View details

Niek van Til

Assistant professor

Amsterdam UMC Locatie VUmc

NETHERLANDS

View details

Uta Griesenbach

Imperial College London

UNITED KINGDOM

View details

Jose-Carlos Segovia

Centro de Investigaciones Energéticas Medioambientales y Tecnológicas

SPAIN

View details

Jeffrey A. Medin

UNITED STATES

View details

Silvana Libertini

Lab head

Novartis Institutes for BioMedical Research Basel

SWITZERLAND

View details

Claire Booth

Senior Clinical Lecturer

University College London Institute of Child Health

UNITED KINGDOM

View details

Eric WFW Alton

Professor of Respiratory Medicine and Gene Therapy

Imperial College London

UNITED KINGDOM

View details

Frank Staal

Professor

Leiden University Medical Center

NETHERLANDS

View details

Catherine Vickers

Head of Innovation

National Research Institute of Animal Production

UNITED KINGDOM

View details

Axel Schambach

Professor

Hannover Medical School

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Rothe

Research Interests

Explore related searches

Recent Grants

Articles (13)

Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1.

Safety and efficacy of gene therapy for RAG1-deficient SCID

Meta-Analysis and Optimization of the <i>In Vitro</i> Immortalization Assay for Safety Assessment of Retroviral Vectors in Gene Therapy.

Targeting BCL11B in CAR-engineered lymphoid progenitors drives NK-like cell development with prolonged anti-leukemic activity.

Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy.

Preclinical lentiviral vector-mediated hematopoietic stem and progenitor cell gene therapy corrects Pompe disease-related muscle and neurological manifestations

Improving the Assessment of Risk Factors Relevant to Potential Carcinogenicity of Gene Therapies: A Consensus Article

Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials.

Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1.

Development of an <i>in vitro</i> genotoxicity assay to detect retroviral vector-induced lymphoid insertional mutants.

TGF<i>β</i> Inhibitor A83-01 Enhances Murine HSPC Expansion for Gene Therapy.

Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease

Inflammation-inducible promoters to overexpress immune inhibitory factors by MSCs.

Collaborators (11)

Jordi Barquinero

Niek van Til

Uta Griesenbach

Jose-Carlos Segovia

Jeffrey A. Medin

Silvana Libertini

Claire Booth

Eric WFW Alton

Frank Staal

Catherine Vickers

Axel Schambach

Make your next move.

Michael Rothe

Research Interests

Explore related searches

Recent Grants

Articles (13)

Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1.

Safety and efficacy of gene therapy for RAG1-deficient SCID

Meta-Analysis and Optimization of the &lt;i&gt;In Vitro&lt;/i&gt; Immortalization Assay for Safety Assessment of Retroviral Vectors in Gene Therapy.

Targeting BCL11B in CAR-engineered lymphoid progenitors drives NK-like cell development with prolonged anti-leukemic activity.

Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy.

Preclinical lentiviral vector-mediated hematopoietic stem and progenitor cell gene therapy corrects Pompe disease-related muscle and neurological manifestations

Improving the Assessment of Risk Factors Relevant to Potential Carcinogenicity of Gene Therapies: A Consensus Article

Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials.

Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1.

Development of an <i>in vitro</i> genotoxicity assay to detect retroviral vector-induced lymphoid insertional mutants.

TGF<i>β</i> Inhibitor A83-01 Enhances Murine HSPC Expansion for Gene Therapy.

Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease

Inflammation-inducible promoters to overexpress immune inhibitory factors by MSCs.

Collaborators (11)

Jordi Barquinero

Niek van Til

Uta Griesenbach

Jose-Carlos Segovia

Jeffrey A. Medin

Silvana Libertini

Claire Booth

Eric WFW Alton

Frank Staal

Catherine Vickers

Axel Schambach

Make your next move.

Meta-Analysis and Optimization of the <i>In Vitro</i> Immortalization Assay for Safety Assessment of Retroviral Vectors in Gene Therapy.